.jpg "Ascendis Pharma (NASDAQ: ASND)")
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (NASDAQ: ASND) and Depomed (NASDAQ: DEPO) with bullish sentiments.
Ascendis Pharma (NASDAQ: ASND)
In a report issued on May 15, Liana Moussatos from Wedbush reiterated a Buy rating on Ascendis Pharma (NASDAQ: ASND), with a price target of $76. The company’s shares closed yesterday at $68, close to its 52-week high of $70.50.
According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 9.7% and a 44.2% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.
Currently, the analyst consensus on Ascendis Pharma is Moderate Buy and the average price target is $68.33, representing a 0.5% upside.
In a report issued on May 14, J.P. Morgan also reiterated a Buy rating on the stock with a $79 price target.
See today’s analyst top recommended stocks >>
Depomed (NASDAQ: DEPO)
Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Depomed (NASDAQ: DEPO) yesterday and set a price target of $9. The company’s shares closed yesterday at $7.52.
Rivkind Koffler commented:
“We reiterate our Buy rating and $9 price target following a 1Q:18 beat. We expect quarters to sequentially improve throughout 2018, which we view as a transformational year for Depomed.”
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.5% and a 48.8% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Adamas Pharmaceuticals, and Eagle Pharmaceuticals.
Depomed has an analyst consensus of Moderate Buy, with a price target consensus of $9.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
